|
CN111068360A
|
|
Combined chromatographic device and continuous flow chromatographic method
|
|
CN110777118A
|
|
Engineering cell strain capable of stably expressing human RANK gene and application thereof
|
|
CN110551216A
|
|
Multivalent anti-OX 40 antibodies and uses thereof
|
|
CN110305210A
|
|
Novel antibody molecules, Its Preparation Method And Use
|
|
CN109970856A
|
|
Anti-lag-3 antibody and application thereof
|
|
CN109970857A
|
|
Anti- PD-L1 antibody and application thereof
|
|
CN109970860A
|
|
Three chain antibodies, Its Preparation Method And Use
|
|
CN110615840A
|
|
Fully human anti-LAG-3 antibodies and uses thereof
|
|
CN110684048A
|
|
Novel phosphoinositide 3-kinase inhibitor and preparation method and application thereof
|
|
CN110357813A
|
|
A kind of new indole amine 2,3- dioxygenase inhibitor and its preparation method and application
|
|
CN106916226A
|
|
Immunoregulation medicament with CTLA 4 as target spot treats application lungy
|
|
CN106913869A
|
|
A kind of monoclonal antibody formulations of anti-CTLA 4 and its application
|
|
CN106908528A
|
|
The detection method of sialic acid in protein medicaments
|
|
CN108239150A
|
|
Anti- PCSK9 antibody and application thereof
|
|
CN106620691A
|
|
Recombinant fully human anti-CTLA-4 monoclonal antibody preparation and application thereof
|
|
US2018147258A1
|
|
Stable liquid formulations of recombinant fusion proteins
|
|
CN105727285A
|
|
An application of a monoclonal antibody in treatment of neurodegenerative diseases
|
|
CN105435222A
|
|
Recombinant fusion protein preparation
|
|
BR112014013205A2
|
|
fusion protein, its use and production method, pharmaceutical composition, nucleic acid, and kit
|
